NEWS AND ANNOUNCEMENTS
EURETINA 2013, Hamburg: Oraya Seminar Presentations   More >

 

Initial Three-Year Data from INTREPID Study of Non-invasive Therapy for Wet AMD Presented at American Academy of Ophthalmology Annual Meeting

Oraya® Therapeutics, Inc. announced today that initial three-year safety follow-up data from its INTREPID study of Oraya Therapy™ stereotactic radiotherapy for the treatment of wet age-related macular degeneration (AMD) were presented for the first time today during the America Academy of Ophthalmology’s (AAO) annual meeting in New Orleans.   Download >

 

INTREPID Study Demonstrates Two-year Safety and Effectiveness of Non-invasive Therapy for Wet AMD

Oraya Therapeutics, Inc. announced today the two-year results of its INTREPID study of Oraya Therapy™ Stereotactic Radiotherapy for the treatment of wet age-related macular degeneration (AMD).   Download >

Oraya Therapy Centers
Oraya Therapy Centers

The Oraya Therapy is now available at Optegra Eye Hospitals in the United Kingdom, the Vista Clinic in Switzerland and the Clinic for Eye Health in Germany, with additional locations coming soon. Visit our Treatment Locations page for more information about Oraya Therapy Centers.

TREATMENT LOCATIONS

 

INTREPID Study Results — Free Download

For a limited time and while supplies last, Oraya is offering interested physicians a free copy of the INTREPID Study Results published in Ophthalmology, September 2013.   Download >

 

The Jonathan Gathorne-Hardy Story

One of the first wet AMD patients in the world treated with a single 20-minute radiotherapy treatment has had improved vision and no subsequent anti-VEGF injections for two years.  Download a copy of Jonny’s story or watch the video below.

WHAT IS AMD?

Age-Related Macular Degeneration (AMD) is a progressive disease that causes loss of central vision leading to blindness. It is the primary cause of vision loss for seniors in the industrialized world. While there is no cure for AMD, the Oraya Therapy™ for Wet AMD is an exciting new treatment. Age-Related Macular Degeneration (AMD) is a progressive disease that causes loss of central vision leading to blindness. It is the primary cause of vision loss for seniors in the industrialized world. While there is no cure for AMD, the Oraya Therapy™ for Wet AMD is an exciting new treatment.   More >

WHO IS ORAYA?

Founded in 2007, Oraya® Therapeutics, Inc. is a privately held company developing an innovative and non-invasive therapy designed to advance the treatment options for wet AMD.   More >

WHY ORAYA THERAPY?

Physicians and patients require a new option and a new vision for the treatment of wet AMD. Oraya Therapy— intended as a one-time, non-invasive procedure—uses a low-voltage, stereotactic approach. It delivers precisely controlled X-rays confined to the diseased area of interest, sparing the surrounding structures of the eye.   More >

© 2014 All rights reserved to Oraya Therapeutics The IRay® Radiotherapy System is an investigational device and is not available for sale in the U.S.A. Oraya, Oraya Therapy, IRay and I-Guide are either trademarks or registered trademarks of Oraya Therapeutics, Inc. in the United States and other countries.